IL-27-producing B cells in the antibody response
抗体反应中产生 IL-27 的 B 细胞
基本信息
- 批准号:10211938
- 负责人:
- 金额:$ 44.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-02 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAcquired Immunodeficiency SyndromeAddressAffinityAntibodiesAntibody ResponseAntigensAntiviral AgentsB Cell ProliferationB cell differentiationB-Cell ActivationB-Lymphocyte SubsetsB-LymphocytesBacterial InfectionsBindingBiologicalCOVID-19COVID-19 vaccineCell ShapeCellsClinical TrialsDataDevelopmentDifferentiation and GrowthDiphtheriaDiseaseEffector CellElementsGene ExpressionGenerationsGenetic RecombinationGenetic TranscriptionHIVHIV vaccineHaptensHelper-Inducer T-LymphocyteHumanIL6ST geneIgG1IgG3ImmuneImmunizationImmunoglobulin Class SwitchingImmunoglobulin GImmunoglobulin Somatic HypermutationImmunologic ReceptorsImpairmentIn VitroInfectionInfectious AgentInterventionKnowledgeLigandsMalariaMeaslesMediatingMedicalMemory B-LymphocyteModelingMolecularMumpsMusNatureOutputPlaguePlasma CellsPoliomyelitisPositioning AttributeProcessProductionPublic Health PracticeReceptor SignalingRecording of previous eventsRegulationReporterResearchRoleSignal TransductionSmallpoxSmallpox VaccineSourceStimulusStructure of germinal center of lymph nodeTNFSF5 geneTestingTetanusVaccinesVaccinia virusViral AntibodiesViral VaccinesVirusVirus Diseasesacute infectionaluminum sulfatebasechronic infectioncytokinein vivoneutralizing antibodynovelplasma cell differentiationreceptorresponsesuccesssynergismtooltranscription factorvaccine developmentvaccine efficacyvectorvirtual
项目摘要
PROJECT SUMMARY – IL-27-producing B cells in the antibody response
Built on our novel findings that B cells can be induced to express high levels of IL-27 (IL27p28/EBI3 heterodimer),
this proposal will explore molecular and cellular mechanisms underlying the role of IL-27 and IL-27-producing B
cells (B-27 cells) in class-switched antibody (Ab) responses. As we contend, B-27 cells shape the magnitude
and quality of T-dependent Ab responses, including those elicited by viral infections. As we also contend, they
do so as “helper” B cells to enhance the function of their target “effector” B cells, i.e., those responding to antigens
and differentiating into IgG-producing cells. Such class-switched Abs include IgG1, which directly neutralizes
virus, and human IgG3 and mouse IgG2a/IgG2c (IgG2a), which have additional anti-viral effector functions.
Owing to the unique requirement of both innate and adaptive immune receptor signals for their induction, B-27
cells are strategically positioned to mediate the potent effect of TLR ligands in boosting the Ab response.
We hypothesize that B-27 cells are induced in a manner dependent on transcription factor BATF3, and
optimize the Ab response by cooperating with IFNg to promote proliferation, survival and full differentiation of
IgG-producing B cells. This is based on our compelling preliminary data indicating that: (i) as an important
source of IL-27, B cells are induced to produce IL-27 after priming by TLR ligands and then stimulation by Tfh
cell stimuli CD154 and IL-21; (ii) mice with B cell-specific deficiency in Il27p28, Ebi3 or Batf3 are impaired in
IL-27 production and specific IgG2a responses; (iii) IL-27 activates STATs, directs CSR to IgG2a and promotes
survival and plasma cell differentiation in B cells stimulated by CD154 and IL-21 in vitro; and (iv) IL-27 and IFNg
together boost B cell growth and differentiation in vitro, and, conversely, combined IL-27R and IFNgR deficiency
in B cells abrogates specific IgG2a responses and significantly impairs IgG1 responses in vivo.
To test our hypothesis, we will (Aim 1) characterize B-27 cells induced in Tg(Il27p28-Gfp) reporter mice upon
infection by vaccinia virus (VV), which is also used as a vector of a variety of vaccines, or immunization with
conjugated hapten NP-CGG mixed with alum and TLR ligand LPS; and determine the cooperation of B-27 cells
with IFNg in specific IgG responses and underlying effector B cell proliferation, survival, CSR/SHM, plasma cell
and memory B cell differentiation. We will also (Aim 2) address the mechanisms underlying the role of BATF3
in Il27p28 induction by identifying its cis-elements in the Il27p28 locus and partner transcription factors in vitro;
and analyze induction of B cell BATF3 and its impact on B-27 cell generation and Ab responses to VV infection
and NP-CGG/alum/LPS in vivo. Finally, we will (Aim 3) analyze the cooperation of B-cell IL-27R and IFNgR
signals in optimizing effector B cell growth and differentiation in response to VV infection in vivo and stimulation
with CD154 and IL-21 in vitro; and address the underlying mechanisms, focusing on their synergy in regulating
STAT signal outputs and gene expression. By unveiling the mechanisms and function of B-27 cells, our studies
will have a sustained impact on the understanding of IgG responses to viral infections and vaccine development.
项目总结-抗体应答中产生IL-27的B细胞
基于我们的新发现,即B细胞可以被诱导表达高水平的IL-27(IL 27 p28/EBI 3异源二聚体),
该计划将探索IL-27和产生IL-27的B的分子和细胞机制
细胞(B-27细胞)的类别转换抗体(Ab)应答。正如我们所说,B-27细胞塑造了
和T依赖性抗体应答的质量,包括由病毒感染引起的应答。正如我们所主张的,他们
作为“辅助”B细胞来增强其靶“效应”B细胞的功能,即,那些对抗原有反应的
并分化成IgG产生细胞。此类类别转换的Ab包括IgG 1,其直接中和
病毒,以及人IgG 3和小鼠IgG 2a/IgG 2c(IgG 2a),其具有额外的抗病毒效应子功能。
由于先天性和适应性免疫受体信号对它们的诱导的独特要求,B-27
细胞的战略定位是介导TLR配体增强Ab反应的有效作用。
我们假设B-27细胞以依赖于转录因子BATF 3的方式被诱导,
通过与IFNg合作来优化Ab反应,以促进细胞的增殖、存活和完全分化,
产生IgG的B细胞。这是基于我们令人信服的初步数据表明:(一)作为一个重要的
IL-27的来源,B细胞在用TLR配体引发然后用Tfh刺激后被诱导产生IL-27
细胞刺激物CD 154和IL-21;(ii)在IL 27 p28、Ebi 3或Batf 3中具有B细胞特异性缺陷的小鼠,
IL-27产生和特异性IgG 2a应答;(iii)IL-27激活STAT,将CSR引导至IgG 2a,并促进
体外由CD 154和IL-21刺激的B细胞中的存活和浆细胞分化;和(iv)IL-27和IFNg
在体外共同促进B细胞生长和分化,相反,联合IL-27 R和IFN γ R缺乏
在B细胞中,消除特异性IgG 2 a应答并显著损害体内IgG 1应答。
为了检验我们的假设,我们将(目的1)表征在Tg(IL 27 p28-GFP)报告小鼠中诱导的B-27细胞,
通过牛痘病毒(VV)感染,其也用作多种疫苗的载体,或用
结合半抗原NP-CGG与明矾和TLR配体LPS混合,并测定B-27细胞的协同作用
在特异性IgG应答和潜在效应B细胞增殖、存活、CSR/SHM、浆细胞
和记忆B细胞分化。我们还将(目标2)解决的机制,潜在的作用,BATF 3
通过体外鉴定Il 27 p28基因座中的顺式元件和伴侣转录因子来诱导Il 27 p28;
并分析B细胞BATF 3的诱导及其对B-27细胞生成和VV感染的Ab应答的影响
和NP-CGG/明矾/LPS体内。最后,我们将(目的3)分析B细胞IL-27 R和IFNgR的协同作用,
在响应体内VV感染和刺激而优化效应B细胞生长和分化中的信号
与CD 154和IL-21在体外;并解决潜在的机制,重点是它们在调节
STAT信号输出和基因表达。通过揭示B-27细胞的机制和功能,
将对理解IgG对病毒感染的反应和疫苗开发产生持续的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhenming Xu其他文献
Zhenming Xu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhenming Xu', 18)}}的其他基金
IL-27-producing B cells in the antibody response
抗体反应中产生 IL-27 的 B 细胞
- 批准号:
10338194 - 财政年份:2021
- 资助金额:
$ 44.32万 - 项目类别:
IL-27-producing B cells in the antibody response
抗体反应中产生 IL-27 的 B 细胞
- 批准号:
10550179 - 财政年份:2021
- 资助金额:
$ 44.32万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 44.32万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 44.32万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 44.32万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 44.32万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 44.32万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 44.32万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 44.32万 - 项目类别:














{{item.name}}会员




